Transverse Myelitis

Neurologic Clinics

Volumn 31, Issue 1, 2013, Pages 79-138

  Beh, Shin C ^a   Greenberg, Benjamin M ^a   Frohman, Teresa ^a   Frohman, Elliot M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Idiopathic transverse myelitis; Longitudinally extensive transverse myelitis; Lupus myelopathy; Multiple sclerosis; Sjogren's myelopathy; Transverse myelitis

Indexed keywords

4 AMINOPYRIDINE; ANTICONVULSIVE AGENT; ATROPINE; BACLOFEN; BENZODIAZEPINE; BOTULINUM TOXIN A; CAPSAICIN; CISPLATIN; CRANBERRY EXTRACT; CYCLOPHOSPHAMIDE; CYTARABINE; DANTROLENE; DARIFENACIN; FESOTERODINE; FONDAPARINUX; GEMCITABINE; IMMUNOGLOBULIN G; LOW MOLECULAR WEIGHT HEPARIN; METHYLPREDNISOLONE; OLIGOCLONAL BAND; OXYBUTYNIN; RESINIFERATOXIN; SALAZOSULFAPYRIDINE; SOLIFENACIN; SPIDER VENOM; TAMSULOSIN; TIZANIDINE; TOLTERODINE; TROSPIUM CHLORIDE; UNINDEXED DRUG;

ACANTHAMOEBA; ACINETOBACTER BAUMANNII; ACUTE COMPLETE TRANSVERSE MYELITIS; ACUTE DISSEMINATED ENCEPHALOMYELITIS; ACUTE PARTIAL TRANSVERSE MYELITIS; ALPHA TOCOPHEROL DEFICIENCY; ANKLE FOOT ORTHOSIS; ANKYLOSING SPONDYLITIS; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTIFICIAL VENTILATION; ATOPIC MYELITIS; AUTONOMIC DYSFUNCTION; AUTONOMIC DYSREFLEXIA; BABINSKI REFLEX; BARTONELLA HENSELAE; BEHCET DISEASE; BLADDER SPASM; BLEEDING; BORRELIA BURGDORFERI; BROWN SEQUARD SYNDROME; CAMPYLOBACTER JEJUNI; CENTRAL CORD SYNDROME; CEREBROSPINAL FLUID ANALYSIS; CHLAMYDOPHILA PNEUMONIAE; CHLAMYDOPHILA PSITTACI; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONUS MEDULLARIS; COPPER DEFICIENCY; COXIELLA BURNETII; CYANOCOBALAMIN DEFICIENCY; DECUBITUS; DETRUSOR DYSSYNERGIA; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DRUG MEGADOSE; EJACULATION DISORDER; ELECTROMYOGRAPHY; EPIDURAL ANESTHESIA; ERECTILE DYSFUNCTION; EXOSKELETON (REHABILITATION); FECES INCONTINENCE; FOLEY BALLOON CATHETER; FUNCTIONAL ELECTRICAL STIMULATION; GALLBLADDER DISEASE; GRAY MATTER; HEMORRHAGIC CYSTITIS; HEMORRHOID; HEMORRHOID HEMORRHAGE; HUMAN; HYPERREFLEXIA; HYPOTENSION; IDIOPATHIC DISEASE; IMMOBILIZATION; INTERMITTENT CATHETERIZATION; INTERNUCLEAR OPHTHALMOPLEGIA; LATHYRISM; LEGIONELLA PNEUMOPHILA; LEPTOSPIRA; LIBIDO DISORDER; LONGITUDINALLY EXTENSIVE TRANSVERSE MYELITIS; MICTURITION; MULTIPLE SCLEROSIS; MUSCLE STRENGTH; MYCOBACTERIUM TUBERCULOSIS; MYCOPLASMA PNEUMONIAE; MYELITIS; MYELOOPTIC NEUROPATHY; NAUSEA; NERVE CONDUCTION; NEUROGENIC BOWEL; NEUROMODULATION; NEUROMUSCULAR ELECTRICAL STIMULATION; NOCICEPTIVE PAIN; NOCTURIA; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGASM DISORDER; ORIENTIA TSUTSUGAMUSHI; ORTHOSTATIC HYPOTENSION; OSTEOPOROSIS; OVERACTIVE BLADDER; PARAGONIMUS WESTERMANI; PARAINFECTIOUS TRANSVERSE MYELITIS; PARANEOPLASTIC SYNDROME; PARAPLEGIA; PHYSICAL MEDICINE; PHYSIOTHERAPY; PLASMAPHERESIS; PRIORITY JOURNAL; PRURITUS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; ROBOTICS; SALMONELLA PARATYPHI B; SARCOIDOSIS; SCHISTOSOMA; SCHISTOSOMIASIS; SECONDARY TRANSVERSE MYELITIS; SEXUAL DYSFUNCTION; SJOEGREN SYNDROME; SPASTICITY; SPINAL CORD TRANSVERSE LESION; STOMACH PARESIS; STRETCHING EXERCISE; SUBACUTE COMBINED DEGENERATION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TACHYCARDIA; TAENIA SOLIUM; THYMUS HYPERPLASIA; TONIC SEIZURE; TOXOPLASMA GONDII; TRYPANOSOMA BRUCEI; URINARY TRACT INFECTION; URINE INCONTINENCE; URTICARIA; VAGINAL LUBRICATION; VENOUS THROMBOEMBOLISM; VIBRATION; VOGT KOYANAGI SYNDROME; WHITE MATTER; XEROSTOMIA;

HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MYELITIS, TRANSVERSE; SPINAL CORD;

EID: 84870163983     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2012.09.008     Document Type: Review

References (480)

1. Oppenheim H. Zum Capitel der Myelitis. Berl Klin Wchnschr 1891, 28:761.
2. Cree B.A., Wingerchuk D.M. Acute transverse myelitis: is the "idiopathic" form vanishing?. Neurology 2005, 65:1857-1858.
3. Frohman E.M., Wingerchuk D.M. Clinical practice. Transverse myelitis. N Engl J Med 2010, 363(6):564-572.
4. de Seze J., Stojkovic T., Breteau G., et al. Acute myelopathies: clinical, laboratory, and outcome profiles in 79 cases. Brain 2001, 124:1509-1521.
5. Jacob A., Weinshenker B.G. An approach to the diagnosis of acute transverse myelitis. Semin Neurol 2008, 28:105-120.
6. Wingerchuk D.M. Postinfectious encephalomyelitis. Curr Neurol Neurosci Rep 2003, 3:256-264.
7. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002, 59:499-505. Transverse Myelitis Consortium Group.
8. Berman M., Feldman S., Alter M., et al. Acute transverse myelitis: incidence and etiologic considerations. Neurology 1981, 31:966-971.
9. Jeffrey D.R., Mandler R.N., Davis L.E. Transverse myelitis. Retrospective analysis of 33 cases, with differentiation of cases associated with multiple sclerosis and parainfectious events. Arch Neurol 1993, 50:532-535.
10. Bhat A., Naguwa S., Cheema G., et al. The epidemiology of transverse myelitis. Autoimmun Rev 2010, 9:A395-A399.
11. Debette S., de Seze J., Pruvo J.P., et al. Long-term outcome of acute and subacute myelopathies. J Neurol 2009, 256:980-988.
12. Christensen P.B., Wermuth L., Mulder D.W., et al. Clinical course and long-term prognosis of acute transverse myelopathy. Acta Neurol Scand 1990, 81:431-435.
13. Scott T.F., Frohman E.M., de Seze J., et al. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011, 77(24):2128-2134.
14. Ditunno J.F., Little J.W., Tessler A., et al. Spinal shock revisited: a four-phase model. Spinal Cord 2004, 42(7):383-395.
15. Fogelson J., Williams K. Compressive and traumatic myelopathies. Continuum (Minneap Minn) 2008, 14(3):110-133.
16. Bakheit A.M. Phantom limb sensations after complete thoracic transverse myelitis. J Neurol Neurosurg Psychiatry 2000, 69(2):275-276.
17. Kempster P.A., Rollinson R.D. The Lhermitte phenomenon: variant forms and their significance. J Clin Neurosci 2008, 15(4):379-381.
18. Layzer R.B. Myeloneuropathy after prolonged exposure to nitrous oxide. Lancet 1978, 312(8102):1227-1230.
19. Todd N.V. Priapism in acute spinal cord injury. Spinal Cord 2011, 49(10):1033-1035.
20. Hammond E.R., Kerr D.A. Priapism in infantile transverse myelitis. Arch Neurol 2009, 66(7):894-897.
21. Kim S.M., Go M.J., Sung J.J., et al. Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility and clinical characteristics. Arch Neurol 2012, 69(8):1026-1031.
22. Tashiro K. Charles Edward Beevor. J Neurol 2001, 248:635-636.
23. Brazis P.W., Masdeu J.C., Biller J. Spinal cord. Localization in clinical neurology 2007, 99-123. Lippincott Williams & Wilkins, Philadelphia. 5th edition.
24. Blumenfeld H. The neurologic exam as a lesson in neuroanatomy. Neuroanatomy through clinical cases 2002, 49-82. Sinauer Associates, Inc, Sunderland (MA).
25. Wingerchuk D.M., Hogancamp W.F., O'Brien P.C., et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999, 53(5):1107-1114.
26. Palace J., Leite M.I., Nairne A., et al. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 2010, 67(8):1016-1017.
27. Bot J.C., Barkhof F., Lycklama à Nijeholt G.J., et al. Comparison of a conventional cardiac-triggered dual spin-echo and a fast STIR sequence in detection of spinal cord lesions in multiple sclerosis. Eur Radiol 2000, 10(5):753-758.
28. Campi A., Pontesilli S., Gerevini S., et al. Comparison of MRI pulse sequences for investigation of lesions of the cervical spinal cord. Neuroradiology 2000, 42(9):669-675.
29. Scott T.F. Nosology of idiopathic transverse myelitis syndromes. Acta Neurol Scand 2007, 115:371-376.
30. Scott T.F., Kassab S.L., Singh S. Acute partial transverse myelitis with normal cerebral magnetic resonance imaging: transition rate to clinically definite multiple sclerosis. Mult Scler 2005, 11(4):373-377.
31. Lennon V.A., Wingerchuk D.M., Kryzer T.J., et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 364:2106-2112.
32. Weinshenker B.G., Wingerchuk D.M., Vukusic S., et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006, 59:566-569.
33. McLean B.N., Luxton R.W., Thompson E.J. A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the log IgG-index. A comparison and diagnostic applications. Brain 1990, 113(Pt 5):1269-1289.
34. Rodriguez A., Calogne M., Pedroza-Seres M., et al. Referral patterns of uveitis in a tertiary eye care center. Arch Ophthalmol 1996, 114(5):593-599.
35. Frohman E.M., Frohman T.C., Zee D.S., et al. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol 2005, 4(2):111-121.
36. Syme J.A., Kelly J.J. Absent F-waves early in a case of transverse myelitis. Muscle Nerve 1994, 17:462-465.
37. Misra U.K., Kalita J. Can electromyography predict the prognosis of transverse myelitis?. J Neurol 1998, 245:741-744.
38. Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 2006, 354:942-955.
39. Cordonnier C., de Seze J., Breteau G., et al. Prospective study of patients presenting with acute partial transverse myelopathy. J Neurol 2003, 250(12):1447-1452.
40. Harzheim M., Schlegel U., Urbach H., et al. Discriminatory features of acute transverse myelitis: a retrospective analysis of 45 patients. J Neurol Sci 2004, 217:217-223.
41. Bruna J., Martinez-Yelamos S., Martinez-Yelamos A., et al. Idiopathic acute transverse myelitis: a clinical study and prognostic markers in 45 cases. Mult Scler 2006, 12(2):169-173.
42. Sellner J., Luthi N., Buhler R., et al. Acute partial transverse myelitis: risk factors for conversion to multiple sclerosis. Eur J Neurol 2008, 15(4):398-405.
43. Bourre B., Zephir H., Ongagna J.C., et al. Long-term follow-up of acute partial transverse myelitis. Arch Neurol 2012, 69(3):357-362.
44. Fisniku L.K., Brex P.A., Altmann D.R., et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008, 131:808-817.
45. Barkhof F., Filippi M., Miller D.H., et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997, 120(pt 11):2059-2069.
46. Bashir K., Whitaker J.N. Importance of paraclinical and CSF studies in the diagnosis of MS in patients presenting with partial cervical transverse myelopathy and negative cranial MRI. Mult Scler 2000, 6:312-316.
47. O'Riordan J.I., Thompson A.J., Kingsley D.P., et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNSA 10-year follow up. Brain 1998, 121:495-503.
48. Martinelli V., Comi G., Rovaris M., et al. Acute myelopathy of unknown etiology: a clinical, neurophysiological and MRI study of short and long-term prognostic factors. J Neurol 1995, 242:497-503.
49. Perumal J., Zabad R., Caon C., et al. Acute transverse myelitis with normal brain MRI: long-term risk of MS. J Neurol 2008, 255(1):89-93.
50. Qiu W., Wu J.S., Zhang M.N., et al. Longitudinally extensive myelopathy in Caucasians: a West Australian study of 26 cases from the Perth Demyelinating Diseases Database. J Neurol Neurosurg Psychiatry 2010, 81:209-212.
51. Wingerchuk D.M., Lennon V.A., Pittock S.J., et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66:1485-1489.
52. Pittock S.J., Lennon V.A., de Seze J., et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008, 65:78-83.
53. Wingerchuk D.M., Lennon V.A., Lucchinetti C.F., et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007, 6:805-815.
54. Jarius S., Jacobi C., de Seze J., et al. Frequency and specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler 2011, 17(9):1067-1073.
55. Vitali C., Bombardieri S., Jonsson R., et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002, 61:554-558.
56. Govoni M., Padovan M., Rizzo N., et al. CNS involvement in primary Sjogren's syndrome: prevalence, clinical aspects, diagnostic assessment and therapeutic approach. CNS Drugs 2001, 15:597-607.
57. Delalande S., de Seze J., Fauchais A.L., et al. Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) 2004, 83:280-291.
58. Alexander E.L., Provost T.T., Stevens M.D., et al. Neurologic complications of primary Sjögren's syndrome. Medicine (Baltimore) 1982, 61:247-257.
59. Escudero D., Latorre P., Codina M., et al. Central nervous system disease in Sjögren's syndrome. Ann Med Interne (Paris) 1995, 146:239-242.
60. Kim S.M., Water P., Vincent A., et al. Sjögren's syndrome myelopathy: spinal cord involvement in Sjogren's syndrome might be a manifestation of NMO. Mult Scler 2009, 15:1062-1068.
61. Konttinen Y.T., Kinnunen E., Von Bonsdorff M., et al. Acute transverse myelopathy successfully treated with plasmapheresis and prednisone in a patient with primary Sjogren's syndrome. Arthritis Rheum 1987, 30:339-344.
62. Canhao H., Fonseca J.E., Rosa A. Intravenous gammaglobulin in the treatment of central nervous system vasculitis associated with Sjögren's syndrome. J Rheumatol 2000, 27:1102-1103.
63. Alcântara C., Gomes M.J., Ferreira C. Rituximab therapy in primary Sjögren's syndrome. Ann N Y Acad Sci 2009, 1173:701-705. (Contemporary Challenges in Autoimmunity).
64. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40(9):1725.
65. West S.G. Neuropsychiatric lupus. Rheum Dis Clin North Am 1994, 20(1):129-158.
66. Eckstein C., Saidha S., Levy M. A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis. J Neurol 2012, 259(5):801-816.
67. Kovacs B., LaVerty T., Brent L., et al. Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis 2000, 59:120-124.
68. Schulz S.W., Shenin M., Mehta A., et al. Initial presentation of acute transverse myelitis in systemic lupus erythematosus: demographics, diagnosis, management and comparison to idiopathic cases. Rheumatol Int 2012, 32(9):2623-2627.
69. Katsiari C.G., Giavri I., Mitsikostas D.D., et al. Acute transverse myelitis and antiphospholipid antibodies in lupus. No evidence for anticoagulation. Eur J Neurol 2011, 18(4):556-563.
70. Bertsias G.K., Ioannidis J.P., Aringer M., et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010, 69(12):2074-2082.
71. Espinosa G., Mendizabal A., Minguez S., et al. Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients. Semin Arthritis Rheum 2010, 39(4):246-256.
72. Birnbaum J., Petri M., Thompson R., et al. Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum 2009, 60(11):3378-3387.
73. D'Cruz D.P., Mellor-Pita S., Joven B., et al. Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. J Rheumatol 2004, 31:280-285.
74. Tellez-Zenteno J.F., Remes-Troche J.M., Negrete-Pulido R.O., et al. Longitudinal myelitis associated with systemic lupus erythematosus: clinical features and magnetic resonance imaging of six cases. Lupus 2001, 10:851-856.
75. Provenzale J.M., Barboriak D.P., Gaensler R.L., et al. Lupus-related myelitis: serial MR findings. Am J Neuroradiol 1994, 15:1911-1917.
76. Salmaggi A., Lamperti E., Eoli M., et al. Spinal cord involvement and systemic lupus erythematosus: clinical and magnetic resonance findings in 5 patients. Clin Exp Rheumatol 1994, 12:389-394.
77. Mok C.C., Lau C.S., Chan E.Y.T., et al. Acute transverse myelopathy in systemic lupus erythematosus: clinical presentation, treatment and outcome. J Rheumatol 1998, 25:467-473.
78. Deodhar A.A., Hochenedl T., Bennett R.M. Longitudinal involvement of the spinal cord in a patient with lupus related transverse myelitis. J Rheumatol 1999, 26:446-449.
79. Neumann-Andersen G., Lindgren S. Involvement of the entire spinal cord and medulla oblongata in acute catastrophic-onset transverse myelitis in SLE. Clin Rheumatol 2000, 19:156-160.
80. Katramados A.M., Rabah R., Adams M.D., et al. Longitudinal myelitis, aseptic meningitis, and conus medullaris infarction as presenting manifestations of pediatric systemic lupus erythematosus. Lupus 2008, 17:332-336.
81. Theodoridou A., Settas L. Demyelination in rheumatic diseases. Postgrad Med J 2008, 84:127-132.
82. Barile-Fabris L., Ariza-Andraca R., Olguin-Ortega L., et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprenisolone in severe neurological manifestations in systemic lupus erythematous. Ann Rheum Dis 2005, 64:620-625.
83. Sherer Y., Hassin S., Shoenfeld Y., et al. Transverse myelitis in patients with antiphospholipid antibodies-the importance of early diagnosis and treatment. Clin Rheumatol 2002, 21:207-210.
84. Harisdangkul V., Doorenbos D., Subramony S.H. Lupus transverse myelopathy: better outcome with early recognition and aggressive high-dose intravenous corticosteroid pulse treatment. J Neurol 1995, 242:326-331.
85. Neuwelt C.M. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. Ther Apher Dial 2003, 7:173-182.
86. Bartolucci P., Bréchignac S., Cohen P., et al. Adjunctive plasma exchanges to treat neuropsychiatric lupus: a retrospective study on 10 patients. Lupus 2007, 16:817-822.
87. Armstrong D.J., McCarron M.T., Wright G.D. SLE-associated transverse myelitis successfully treated with rituximab (anti-CD20 monoclonal antibody). Rheumatol Int 2006, 26:771-772.
88. Ye Y., Qian J., Gu Y., et al. Rituximab in the treatment of severe lupus myelopathy. Clin Rheumatol 2011, 30(7):981-986.
89. Lu X., Gu Y., Wang Y., et al. Prognostic factors of lupus myelopathy. Lupus 2008, 17:323-328.
90. Wilson W.A., Gharavi A.E., Koike T., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999, 42(7):1309-1311.
91. Cervera R., Piette J.C., Font J., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002, 46:1019-1027.
92. Kim J.H., Lee S.I., Park S.I., et al. Recurrent transverse myelitis in primary antiphospholipid syndrome: case report and literature review. Rheumatol Int 2004, 24:244-246.
93. Rodrigues C.E., de Carvalho J.F. Clinical, radiologic, and therapeutic analysis of 14 patients with transverse myelitis associated with antiphospholipid syndrome: report of 4 cases and review of the literature. Semin Arthritis Rheum 2011, 40(4):349-357.
94. Tristano A.G. Acute transverse myelitis as part of the catastrophic antiphospholipid syndrome in a systemic lupus erythematosus patient. Neurologia 2004, 19:774-775.
95. Rodrigues C.E., Carvalho J.F., Shoenfeld Y. Neurological manifestations of antiphospholipid syndrome. Eur J Clin Invest 2010, 40(4):350-359.
96. Tourbah A., Clapin A., Gout O., et al. Systemic autoimmune features and multiple sclerosis. A 5-year follow up. Arch Neurol 1998, 55:517-521.
97. Roussel V., Yi F., Jauberteau O., et al. Prevalence and clinical significance of antiphospholipid antibodies in multiple sclerosis: a study of 89 patients. J Autoimmun 2000, 14:259-265.
98. Gaarg N., Zivadinov R., Ramanathan M., et al. Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. J Neuroimmunol 2007, 187:159-165.
99. Stosic M., Ambrus J., Garg N., et al. MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis. J Neurol 2010, 257(1):63-71.
100. Szmyrka-Kaczmarek M., Pokryszko-Dragan A., Pawlik B., et al. Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis. Lupus 2012, 21:412-420.
101. The International Study Group for Behcet's disease. Criteria for diagnosis of Behcet's disease. Lancet 1990, 335:1078-1080.
102. Al-Araji A., Kidd D. Neuro-Behcet's disease: epidemiology, clinical characteristics, and management. Lancet Neurol 2009, 8:192-204.
103. Yesilot N., Mutlu M., Gungoer O., et al. Clinical characteristics and course of spinal cord involvement in Behcet's disease. Eur J Neurol 2007, 14:729-737.
104. Ideguchi H., Suda A., Takeno M., et al. Neurological manifestations of Behcet's disease in Japan: a study of 54 patients. J Neurol 2010, 257(6):1012-1020.
105. Akman-Demir G., Serdaroglu P., Tasci B., et al. Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. Brain 1999, 122:2171-2181.
106. Moskau S., Urbach H., Hartmann A., et al. Multifocal myelitis in Behcet's disease. Neurology 2003, 60(3):517.
107. Kocer N., Islak C., Siva A., et al. CNS involvement in neuro-Behcet syndrome: an MR study. AJNR Am J Neuroradiol 1999, 20:1015-1024.
108. Monaco A.L., Corte R.L., Caniatti L., et al. Neurological involvement in North Italian patients with Behcet's disease. Rheumatol Int 2006, 26:1113-1119.
109. Lee S.H., Yoon P.H., Park S.J., et al. MRI findings in neuro-Behcet's disease. Clinical Radiol 2001, 56:485-494.
110. Fukae J., Noda K., Fujishima K., et al. Subacute longitudinal myelitis associated with Behcet's disease. Intern Med 2010, 49:343-347.
111. Morrissey S.P., Miller D.H., Hermaszewski R., et al. Magnetic resonance imaging of the central nervous system in Behcet's disease. Eur Neurol 1993, 33:287-293.
112. Yoshioka H., Matsubara T., Miyanomae Y., et al. Spinal cord MRI in neuro-Behcet's disease. Neuroradiology 1996, 38:661-662.
113. Mascalchi M., Cosottini M., Cellerini M., et al. MRI of spinal cord involvement in Behcet's disease: case report. Neuroradiology 1998, 40(4):255-257.
114. Green A.L., Mitchell P.J. Spinal cord neuro-Behcet's disease detected on magnetic resonance imaging. Australas Radiol 2000, 44(2):201-203.
115. Desphande D.M., Krishnan C., Kerr D.A. Transverse myelitis after lumbar steroid injection in a patient with Behcet's disease. Spinal Cord 2005, 43:735-737.
116. Vuolo L., Bonzano L., Roccatagliata C., et al. Reversibility of brain lesions in a case of neuro-Behcet's disease studied by MR diffusion. Neurol Sci 2010, 31(2):213-215.
117. Kidd D., Steuer A., Denman A.M., et al. Neurological complications in Behçet's syndrome. Brain 1999, 122:2183-2194.
118. Coban O., Bahar S., Akman-Demir G., et al. Masked assessment of MRI findings: is it possible to differentiate neuro-Behcet's disease from other central nervous system. Neuroradiology 1999, 41:255-260.
119. Zhao B., He L., Lai X.H. A case of neuro-Behcet's disease presenting with lumbar spinal cord involvement. Spinal Cord 2010, 48:172-173.
120. Piptone N., Olivieri I., Padula A., et al. Infliximab for the treatment of neuro-Behcet's disease: a case series and review of the literature. Arthritis Rheum 2008, 59:285-290.
121. Serkova N.J., Christians U., Benet L.Z. Biochemical mechanisms of cyclosporine neurotoxicity. Mol Interv 2004, 4:97-107.
122. Kotake S., Higashi K., Yoshikawa K., et al. Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. Ophthalmology 1999, 106:586-589.
123. Kato Y., Numaga J., Kato S., et al. Central nervous system symptoms in a population of Behçet's disease patients with refractory uveitis treated with cyclosporine A. Clin Experiment Ophthalmol 2001, 29:335-336.
124. Kötter I., Günaydin I., Batra M., et al. CNS involvement occurs more frequently in patients with Behçet's disease under cyclosporin A (CSA) than under other medications: results of a retrospective analysis of 117 cases. Clin Rheumatol 2006, 25:482-486.
125. Lower E.E., Broderick J.P., Brott T.G., et al. Diagnosis and management of neurological sarcoidosis. Arch Intern Med 1997, 157(16):1864-1868.
126. Chapelon C., Ziza J.M., Piette J.C., et al. Neurosarcoidosis: signs, course and treatment in 35 confirmed cases. Medicine (Baltimore) 1990, 69(5):261-276.
127. Stern B.J., Krumholz A., Johns C., et al. Sarcoidosis and its neurological manifestations. Arch Neurol 1985, 42(9):909-917.
128. Delaney P. Neurologic manifestations in sarcoidosis: review of the literature, with a report of 23 cases. Ann Intern Med 1977, 87(3):336-345.
129. Saleh S., Saw C., Marzouk K., et al. Sarcoidosis of the spinal cord: literature review and report of eight cases. J Natl Med Assoc 2006, 98:965-976.
130. Joseph F.G., Scolding N.J. Neurosarcoidosis: a study of 30 new cases. J Neurol Neurosurg Psychiatry 2009, 80(3):297-304.
131. Cohen-Aubart F., Galanaud D., Grabli D., et al. Spinal cord sarcoidosis: clinical and laboratory profile and outcome of 31 patients in a case-control study. Medicine (Baltimore) 2010, 89(2):133-140.
132. Christoforidis G.A., Spickler E.M., Recio M.V., et al. MR of CNS sarcoidosis: correlation of imaging features to clinical symptoms and response to treatment. AJNR Am J Neuroradiol 1999, 20(4):655-669.
133. Bhagavati S., Choi J. Intramedullary cervical spinal cord sarcoidosis. Spinal Cord 2009, 47:179-181.
134. Terada T., Shigeno K., Hori M., et al. Isolated spinal neurosarcoidosis: an autopsy case. Spinal Cord 2010, 48:776-778.
135. Lidar M., Dori A., Levy Y., et al. Sarcoidosis presenting as "corset-like" myelopathy: a description of six cases and literature review. Clin Rev Allergy Immunol 2010, 38(2-3):270-275.
136. Marangoni S., Argentiero V., Tavolato B., Neurosarcoidosis Clinical description of 7 cases with a proposal for a new diagnostic strategy. J Neurol 2006, 253(4):488-495.
137. Spencer T.S., Campellone J.V., Maldonado I., et al. Clinical and magnetic resonance imaging manifestations of neurosarcoidosis. Semin Arthritis Rheum 2005, 34:649-661.
138. Kumar N., Frohman E.M. Spinal neurosarcoidosis mimicking an idiopathic inflammatory demyelinating syndrome. Arch Neurol 2004, 61(4):586-589.
139. Sakushima K., Yabe I., Nakano F., et al. Clinical features of spinal cord sarcoidosis: analysis of 17 neurosarcoidosis patients. J Neurol 2011, 258(12):2163-2167.
140. Zajicek J.P., Scolding N.J., Foster O., et al. Central nervous system sarcoidosis-diagnosis and management. QJM 1999, 92(2):103-107.
141. Shah R., Roberson G.H., Cure J.K. Correlation of MR imaging findings and clinical manifestations in neurosarcoidosis. AJNR Am J Neuroradiol 2009, 30:953-961.
142. Sulavik S.B., Spencer R.P., Weed D.A., et al. Recognition of distinctive patterns of gallium-67 distribution in sarcoidosis. J Nucl Med 1990, 31:1909-1914.
143. Dale J.C., O'Brien J.F. Determination of angiotensin-converting enzyme levels in cerebrospinal fluid is not a useful test for the diagnosis of neurosarcoidosis. Mayo Clin Proc 1999, 74(5):535.
144. Read R.W., Holland G.N., Rao N.A., et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of the international committee on nomenclature. Am J Ophthalmol 2001, 131(5):647-652.
145. Lubin J.R., Lowenstein J.I., Fredrick A.R. VKH syndrome with focal neurological signs. Am J Ophthalmol 1981, 91(3):332-341.
146. Dahbour S.S. MRI documented acute myelitis in a patient with Vogt-Koyanagi-Harada syndrome: first report. Clin Neurol Neurosurg 2009, 111(2):200-202.
147. Rajendram R., Evans M., Khurana R.N., et al. Vogt-Koyanagi-Harada disease presenting as optic neuritis. Int Ophthalmol 2007, 27(2-3):217-220.
148. Tahara T., Sekitani T. Neurotological evaluation of Harada's disease. Acta Otolaryngol Suppl 1995, 519:110-113.
149. Miyanaga M., Kawaguchi T., Shimuzu K., et al. Influence of early cerebrospinal fluid-guided diagnosis and early high-dose corticosteroid therapy on ocular outcomes of Vogt-Koyanagi-Harada disease. Int Ophthalmol 2007, 27(2-3):183-188.
150. Miller D.H., Weinshenker B.G., Filippi M., et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008, 14(9):1157-1174.
151. Tenenbaum S., Chitnis T., Ness J., et al. Acute disseminated encephalomyelitis. Neurology 2007, 68(16 Suppl 2):S32-S36.
152. Straussberg R., Schonfeld T., Weitz R., et al. Improvement of atypical acute disseminated encephalomyelitis with steroids and intravenous immunoglobulins. Pediatr Neurol 2001, 24:139-143.
153. Aimoto Y., Moriwaka F., Matsumoto K., et al. A case of acute disseminated encephalomyelitis (ADEM) associated with demyelinating peripheral neuropathy. No To Shinkei 1996, 48:857-860.
154. Torisu H., Kira R., Ishizaki Y., et al. Clinical study of childhood acute disseminated encephalomyelitis, multiple sclerosis, and acute transverse myelitis in Fukuoka Prefecture, Japan. Brain Dev 2010, 32(6):454-462.
155. Huynh W., Cordato D.J., Kehdi E., et al. Post-vaccination encephalomyelitis: literature review and illustrative case. J Clin Neurosci 2008, 15(12):1315-1322.
156. Callen D.J., Shroff M.M., Branson H.M., et al. Role of MRI in the differentiation of ADEM from MS in children. Neurology 2009, 72(11):968-973.
157. Kesselring J., Miller D.H., Robb S.A., et al. Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. Brain 1990, 113:291-302.
158. Kimura S., Nezu A., Ohtsuki N., et al. Serial magnetic resonance imaging in children with postinfectious encephalitis. Brain Dev 1996, 18:461-465.
159. Franciotta D., Columba-Cabezas S., Andreoni L., et al. Oligoclonal IgG band patterns in inflammatory demyelinating human and mouse diseases. J Neuroimmunol 2008, 200(1-2):125-128.
160. Stuve O., Nessler S., Hartung H.P., et al. Acute disseminated encephalomyelitis: pathogenesis, diagnosis, treatment, and prognosis. Nervenarzt 2005, 76(6):701-707.
161. Straub J., Chofflon M., Delavelle J. Early high-dose intravenous methylprednisolone in acute disseminated encephalomyelitis: a successful recovery. Neurology 1997, 49(4):1145-1147.
162. Stricker R.B., Miller R.G., Kiprov D.D. Role of plasmapheresis in acute disseminated (post-infectious) encephalomyelitis. J Clin Apher 1992, 7(4):173-179.
163. Weinshenker B.G., O'Brien P.C., Petterson T.M., et al. A randomized trial of plasma exchange in acute CNS inflammatory demyelinating disease. Ann Neurol 1999, 46:878-886.
164. Llufriu S., Castillo J., Blanco Y., et al. Plasma exchange for acute attacks of CNS demyelination: predictors of improvement at 6 months. Neurology 2009, 73(12):949-953.
165. Keegan M., Pineda A.A., McClelland R.L., et al. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002, 58:143-146.
166. Stübgen J.P. Immune-mediated myelitis associated with hepatitis virus infections. J Neuroimmunol 2011, 239(1-2):21-27.
167. Takahashi-Fujigasaki J., Takagi S., Sakamoto T., et al. Spinal cord biopsy findings of anti-aquaporin-4 antibody-negative recurrent longitudinal myelitis in a patient with sicca symptoms and hepatitis C viral infection. Neuropathology 2009, 29(4):472-479.
168. Aktipi K.M., Ravaglia S., Ceroni M., et al. Severe recurrent myelitis in patients with hepatitis C virus infection. Neurology 2007, 68:468-469.
169. Pacheco V.H., Acharya J.N. Recurrent myelopathy and hepatitis C infection. Ann Neurol 2006, 60(Suppl 3):S45.
170. Grewal A.K., Lopes M.B., Berg C.L., et al. Recurrent demyelinating myelitis associated with hepatitis C viral infection. J Neurol Sci 2004, 224:101-106.
171. Sobukawa E., Sakimura K., Hoshino S., et al. Hepatic myelopathy: an unusual neurological complication of advanced hepatic disease. Intern Med 1994, 33:718-722.
172. Mandal K., Chopra N. Acute transverse myelitis following hepatitis E virus infection. Indian Pediatr 2006, 43:365-366.
173. Seet R.C., Lim E.C., Wilder-Smith E.P. Acute transverse myelitis following dengue virus infection. J Clin Virol 2006, 35(3):310-312.
174. Kusuhara T., Nakajima M., Inoue H., et al. Parainfectious encephalomyeloradiculitis associated with herpes simplex virus 1 DNA in cerebrospinal fluid. Clin Infect DIs 2002, 34(9):1199-1205.
175. Larik A., Chiong Y., Lee L.C., et al. Longitudinally extensive transverse myelitis associated with dengue fever. BMJ Case Rep 2012, pii: bcr1220115378. 10.1136/bcr.12.2011.5378.
176. Chanthamat N., Sathirapanya P. Acute transverse myelitis associated with dengue viral infection. J Spinal Cord Med 2010, 33(4):425-427.
177. Kincaid O., Lipton H.L. Viral myelitis: an update. Curr Neurol Neurosci Rep 2006, 6(6):469-474.
178. Roos K.L. West Nile encephalitis and myelitis. Curr Opin Neurol 2004, 17:343-346.
179. Solomon T., Dung N.M., Kneen R., et al. Japanese encephalitis. J Neurol Neurosurg Psychiatry 2000, 68:405-415.
180. Einsiedel L., Kat E., Ravindran J., et al. MR findings in Murray Valley encephalitis. AJNR Am J Neuroradiol 2003, 24:1379-1382.
181. Bender A. Severe tick borne encephalitis with simultaneous brain stem, bithalamic, and spinal cord involvement documented by MRI. J Neurol Neurosurg Psychiatry 2005, 76:135-137.
182. Scheibe F., Hofmann J., Ruprecht K. Parainfectious myelitis associated with parvovirus B19 infection. J Neurol 2010, 257:1557-1558.
183. Barton L.L., Hyndman N.J. Lymphocytic choriomeningitis virus: reemerging central nervous system pathogen. Pediatrics 2000, 105:e35.
184. Arpino C., Curatolo P., Rezza G. Chikungunya and the nervous system: what we do and do not know. Rev Med Virol 2009, 19(3):121-129.
185. Huisa B.N., Chapin J.E., Adair J.C. Central nervous system complications following Hanta virus cardiopulmonary syndrome. J Neurovirol 2009, 15(2):202-205.
186. Unay B., Kendirli T., Meral C., et al. Transverse myelitis due to echovirus type 30. Acta Paediatr 2005, 94(12):1863-1864.
187. Ponka A. Central nervous system manifestations associated with serologically verified Mycoplasma pneumoniae infection. Scand J Infect Dis 1980, 12:175-184.
188. Cassell G.H., Cole B.C. Mycoplasmas as agents of human disease. N Engl J Med 1981, 304:80-89.
189. Koskiniemi M. CNS manifestations associated with Mycoplasma pneumoniae infections: summary of cases at the University of Helsinki and review. Clin Infect Dis 1993, 17(Suppl 1):S52-S57.
190. Tsiodras S., Kelesidis T.H., Kelesidis I., et al. Mycoplasma pneumoniae-associated myelitis: a comprehensive review. Eur J Neurol 2006, 13:112-124.
191. Isoda H., Ramsey R. MR imaging of acute transverse myelitis (myelopathy). Radiat Med 1998, 16:179-186.
192. Goebels N., Helmchen C., Abele-Horn M., et al. Extensive myelitis associated with Mycoplasma pneumoniae infection: magnetic resonance imaging and clinical long-term follow-up. J Neurol 2001, 248:204-208.
193. Csabi G., Komaromy H., Hollody K. Transverse myelitis as a rare, serious complication of Mycoplasma pneumoniae infection. Pediatr Neurol 2009, 41(4):312-313.
194. Gozzard P., Orr D., Sanderson F., et al. Acute transverse myelitis as a rare manifestation of Campylobacter diarrhoea with concomitant disruption of the blood brain barrier. J Clin Neurosci 2012, 19:316-318.
195. Baar I., Jacobs B.C., Govers N., et al. Campylobacter jejuni-induced acute transverse myelitis. Spinal Cord 2007, 45:690-694.
196. Aberle J., Kluwe J., Pawlas F., et al. Severe myelitis following infection with Campylobacter enteritis. Eur J Clin Microbiol Infect Dis 2004, 23:134-135.
197. Huber S., Kappos L., Fuhr P., et al. Combined acute disseminated encephalomyelitis and acute motor axonal neuropathy after vaccination for hepatitis A and infection with Campylobacter jejuni. J Neurol 1999, 246:1204-1206.
198. Orr D., McKendrick M.W., Sharrack B. Acute disseminated encephalomyelitis temporally associated with Campylobacter gastroenteritis. J Neurol Neurosurg Psychiatry 2004, 75:792-793.
199. Gaig C., Valldeoriola F., Saiz A. Acute disseminated encephalomyelitis associated with Campylobacter jejuni infection and antiganglioside GM1 IgG antibodies. J Neurol 2005, 252:613-614.
200. Nasralla C.A., Pay N., Goodpasture H.C., et al. Postinfectious encephalopathy in a child following Campylobacter jejuni enteritis. AJNR Am J Neuroradiol 1993, 14:444-448.
201. Bigi S., Aebi C., Nauer C., et al. Acute transverse myelitis in Lyme neuroborreliosis. Infection 2010, 38(5):413-416.
202. Pourhassan A., Shoja M.M., Tubbs R.S., et al. Acute transverse myelitis secondary to Salmonella paratyphi B infection. Infection 2008, 36(2):170-173.
203. Ubogu E.E., Lindenberg J.R., Werz M.A. Transverse myelitis associated with Acinetobacter baumanii intrathecal pump catheter-related infection. Reg Anesth Pain Med 2003, 28(5):470-474.
204. Waltereit R., Küker W., Jürgens S., et al. Acute transverse myelitis associated with Coxiella burnetii infection. J Neurol 2001, 249(10):1459-1461.
205. Schimmel M.S., Schlesinger Y., Berger I., et al. Transverse myelitis: unusual sequelae of neonatal group B streptococcus disease. J Perinatol 2002, 22(7):580-581.
206. Pickerill R.G., Milder J.E. Transverse myelitis associated with cat-scratch disease in an adult. JAMA 1981, 246:2840-2841.
207. Salgado C.D., Weisse M.E. Transverse myelitis associated with probable cat-scratch disease in a previously healthy pediatric patient. Clin Infect Dis 2000, 31(2):609-611.
208. Williams W., Sunderland R. As sick as a pigeon; psittacosis myelitis. Arch Dis Child 1989, 64:1626-1628.
209. Crook T., Bannister B. Acute transverse myelitis associated with Chlamydia psittaci infection. J Infect 1996, 32(2):151-152.
210. de Lau L.M., Siepman D.A., Remmers M.J., et al. Acute disseminating encephalomyelitis following Legionnaires disease. Arch Neurol 2010, 67(5):623-626.
211. Lee K.L., Lee J.K., Yim Y.M., et al. Acute transverse myelitis associated with scrub typhus: case report and a review of literature. Diagn Microbiol Infect Dis 2008, 60(2):237-239.
212. Feng Y., Guo N., Liu J., et al. Mycobacteria infection in incomplete transverse myelitis is refractory steroids: a pilot study. Clin Dev Immunol 2011, 2011:501369.
213. Krishnan C., Kaplin A.I., Graber J.S., et al. Recurrent transverse myelitis following neurobrucellosis: immunologic features and beneficial response to immunosuppression. J Neurovirol 2005, 11:225-231.
214. Baylor P., Garoufi A., Karpathios T., et al. Transverse myelitis in 2 patients with Bartonella henselae infection (cat scratch disease). Clin Infect Dis 2007, 45:e42-e45.
215. Gumbo T., Hakim J.G., Mielke J., et al. Cryptococcus myelitis: atypical presentation of a common infection. Clin Infect Dis 2001, 32:1235-1236.
216. Shields G.S., Castillo M. Myelitis caused by Cladophialophora bantiana. AJR Am J Roentgenol 2002, 179:278-279.
217. Jabbour R.A., Kanj S.S., Sawaya R.A., et al. Toxocara canis myelitis: clinical features, magnetic resonance imaging (MRI) findings, and treatment outcome in 17 patients. Medicine (Baltimore) 2011, 90(5):337-343.
218. Dauriac-Le Masson V., Chochon F., Demeret S., et al. Toxocara canis meningomyelitis. J Neurol 2005, 252(10):1267-1268.
219. Marx C., Lin J., Masruha M.R., et al. Toxocariasis of the CNS simulating acute disseminated encephalomyelitis. Neurology 2007, 69(8):806-807.
220. Helsen G., Vandecasteele S.J., Vanopdenbosch L.J. Toxocariasis presenting as encephalomyelitis. Case Report Med 2011, 2011:503913. 10.1155/2011/503913.
221. Ross A.G., McManus D.P., Farrar J., et al. Neuroschistosomiasis. J Neurol 2012, 259:22-32.
222. Bunyaratavej K., Pongpunlert W., Jongwutiwes S., et al. Spinal gnathostomiasis resembling an intrinsic cord tumor/myelitis in a 4-year-old boy. Southeast Asian J Trop Med Public Health 2008, 39:800-803.
223. Kibiki G.S., Murphy D.K. Transverse myelitis due to trypanosomiasis in a middle aged Tanzanian man. J Neurol Neurosurg Psychiatry 2006, 77:684-685.
224. Drulovic J., Dujmovic I., Stojsavljevic N. Transverse myelopathy in the antiphospholipid antibody syndrome: pinworm infestation as a trigger?. J Neurol Neurosurg Psychiatry 2000, 68:246-256.
225. Lesca G., Deschamps R., Lubetzki C., et al. Acute myelitis in early Borrelia burgdorferi infection. J Neurol 2002, 249:1472-1474.
226. Baumann M., Birnbacher R., Koch J., et al. Uncommon manifestations of neuroborreliosis in children. Eur J Paediatr Neurol 2010, 14:274-277.
227. Bajaj N.P.S., Rose P., Clifford-Jones R., et al. Acute transverse myelitis and Guillain-Barre overlap syndrome with serological evidence for mumps viraemia. Acta Neurol Scand 2001, 104:239-242.
228. Venketasubramanian N. Transverse myelitis following mumps in an adult-a case report with MRI correlation. Acta Neurol Scand 1997, 96:328-331.
229. Rigamonti A., Usai S., Ciusani E., et al. Atypical transverse myelitis due to cytomegalovirus in an immunocompetent patient. Neurol Sci 2005, 26:351-354.
230. Ku B., Lee K. Acute transverse myelitis caused by Coxsackie virus B4 infection: a case report. J Korean Med Sci 1998, 13:449-453.
231. Minami K., Tsuda Y., Maeda H., et al. Acute transverse myelitis caused by Coxsackie virus B5 infection. J Paediatr Child Health 2004, 40:66-68.
232. Chortis P. Study in the therapy of transverse myelitis occurring during tuberculous meningitis. Dis Chest 1958, 33:506-512.
233. McMinn P., Stratov I., Nagarajan L., et al. Neurological manifestations of Enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin Infect Dis 2001, 32(2):236-242.
234. Gruhn B., Meerbach A., Egerer R., et al. Successful treatment of Epstein-Barr virus-induced transverse myelitis with ganciclovir and cytomegalovirus hyperimmune globulin following unrelated bone marrow transplantation. Bone Marrow Transplant 1999, 24:1355-1358.
235. Caldas C., Bernicker E., Dal Nogare A., et al. Case report: transverse myelitis associated with Epstein-Barr virus infection. Am J Med Sci 1994, 307:45-48.
236. Corssmit E.P., Leverstein-van Hall M., Portegies P., et al. Severe neurological complications in association with Epstein-Barr virus infection. J Neurovirol 1997, 3:460-464.
237. Umehara F., Ookatsu H., Hayashi D., et al. MRI studies of spinal visceral larva migrans syndrome. J Neurol Sci 2006, 249:7-12.
238. Lee I.H., Kim S.T., Oh D.K., et al. MRI findings of spinal visceral larva migrans of Toxocara canis. Eur J Radiol 2010, 75:236-240.
239. Joshi T.N., Yamazaki M.K., Zhao H., et al. Spinal schistosomiasis: differential diagnosis for acute paraparesis in a U.S. resident. J Spinal Cord Med 2010, 33(3):256-260.
240. Hull T.P., Bates J.H. Optic neuritis after influenza vaccination. Am J Ophthalmol 1997, 124:703-704.
241. Ray C.L., Dreizin I.J. Bilateral optic neuropathy associated with influenza vaccination. J Neuroophthalmol 1996, 16:182-184.
242. Keegan B.M., Pittock S.J., Lennon V.A. Autoimmune myelopathy associated with collapsin response-mediator protein-5 immunoglobulin G. Ann Neurol 2008, 63(4):531-534.
243. Cross S.A., Salomao D.R., Parisi J.E., et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5 IgG. Ann Neurol 2003, 54:38-50.
244. Pittock S.J., Yoshikawa H., Ahlskog J.E., et al. Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc 2006, 81:1207-1214.
245. Tanaka M., Matsushita T., Tateishi T., et al. Distinct CSF cytokine/chemokine profiles in atopic myelitis and other causes of myelitis. Neurology 2008, 71(13):974-981.
246. Zoli A., Mariano M., Fusari A., et al. Atopic myelitis: first case report outside Japan?. Allergy 2005, 60:410-411.
247. Gregoire S.M., Mormont E., Laloux P., et al. Atopic myelitis: a clinical, biological, radiological and histopathological diagnosis. J Neurol Sci 2006, 247:231-235.
248. Kira J., Kawano Y., Horiuchi I., et al. Clinical, immunological and MRI features of myelitis with atopic dermatitis (atopic myelitis). J Neurol Sci 1999, 162(1):56-61.
249. Kira J., Yamasaki K., Kawano Y., et al. Acute myelitis associated with hyperIgEemia and atopic dermatitis. J Neurol Sci 1997, 148(2):199-203.
250. Isobe N., Kanamori Y., Yonekawa T., et al. First diagnostic criteria for atopic myelitis with special reference to discrimination from myelitis-onset multiple sclerosis. J Neurol Sci 2012, 316:30-35.
251. Constantinescu C.S., Thomas M., Zaman A.G. Atopic optic neuritis. Ocul Immunol Inflamm 2006, 14:125-127.
252. de Seze J., Lanctin C., Lebrun C., et al. Idiopathic acute transverse myelitis: application of the recent diagnostic criteria. Neurology 2005, 65(12):1950-1953.
253. Krishnan C., Kaplin A., Deshpande D., et al. Transverse myelitis: pathogenesis, diagnosis and treatment. Front Biosci 2004, 9:1483-1499.
254. Alvarenga M.P., Thuler L.C., Neto S.P., et al. The clinical course of idiopathic acute transverse myelitis in patients from Rio de Janeiro. J Neurol 2010, 257(6):992-998.
255. Choi K.H., Lee K.S., Chung S.O., et al. Idiopathic transverse myelitis: MR characteristics. AJNR Am J Neuroradiol 1996, 17:1151-1160.
256. Alper G., Petropoulou K.A., Fitz C.R., et al. Idiopathic acute transverse myelitis in children: an analysis and discussion of MRI findings. Mult Scler 2011, 17:74-80.
257. Young J., Quinn S., Hurrell M., et al. Clinically isolated acute transverse myelitis: prognostic features and incidence. Mult Scler 2009, 15(11):1295-1302.
258. Kim S.H., Kim S.M., Vincent A., et al. Clinical characteristics, prognosis, and seropositivity to the anti-aquaporin-4 antibody in Korean patients with longitudinally extensive transverse myelitis. J Neurol 2010, 257(6):920-925.
259. Ravaglia S., Bastianello S., Franciotta D., et al. NMO-IgG-negative relapsing myelitis. Spinal Cord 2009, 47:531-537.
260. Kim K.K. Idiopathic recurrent transverse myelitis. Arch Neurol 2003, 60:1290-1294.
261. Pidcock F.S., Krishnan C., Crawford T.O., et al. Acute transverse myelitis in childhood: center-based analysis of 47 cases. Neurology 2007, 68:1474-1480.
262. Thomas T., Branson H.M., Leonard H., et al. The demographic, clinical and magnetic resonance imaging (MRI) features of transverse myelitis in children. J Child Neurol 2012, 27:11-21.
263. Andronikou S., Albuquerque-Jonathan G., Wilmshurst J., et al. MRI findings in acute idiopathic transverse myelopathy in children. Pediatr Radiol 2003, 33:624-629.
264. Defresne P., Hollenberg H., Husson B., et al. Acute transverse myelitis in children: clinical course and prognostic factors. J Child Neurol 2003, 18:401-406.
265. Knebusch M., Strassburg H.M., Reiners K. Acute transverse myelitis in childhood: nine cases and review of the literature. Dev Med Child Neurol 1998, 40:631-639.
266. Dunne K., Hopkins I.J., Shield L.K. Acute transverse myelopathy in childhood. Dev Med Child Neurol 1986, 28:198-204.
267. Yiu E.M., Kornberg A.J., Ryan M.M., et al. Acute transverse myelitis and acute disseminated encephalomyelitis in childhood: spectrum or separate entities?. J Child Neurol 2009, 24:287-296.
268. De Goede C.G., Holmes E.M., Pike M.G. Acquired transverse myelopathy in children in the United Kingdom-a 2 year prospective study. Eur J Paediatr Neurol 2010, 14:479-487.
269. Banwell B., Tenembaum S., Lennon V.A., et al. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology 2008, 70:344-352.
270. Wang K.C., Wang S.J., Lee C.L., et al. The rescue effect of plasma exchange for neuromyelitis optica. J Clin Neurosci 2011, 18:43-46.
271. Gwathmey K., Balogun R.A., Burns T. Neurologic indications for therapeutic plasma exchange: an update. J Clin Apher 2011, 26(5):261-268.
272. Greenberg B.M., Thomas K.P., Krishnan C., et al. Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide. Neurology 2007, 68(19):1614-1617.
273. Khan O.A., Zvartau-Hind M., Caon C., et al. Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy. Mult Scler 2001, 7:185-188.
274. Smith D. Preliminary analysis of a trial of pulse cyclophosphamide in IFN-beta-resistant active MS. J Neurol Sci 2004, 223:73-79.
275. Borchers A.T., Gershwin M.E. Transverse myelitis. Autoimmun Rev 2012, 11:231-248.
276. Thompson A.J. Neurorehabilitation in multiple sclerosis: foundations, facts and fiction. Curr Opin Neurol 2005, 18:267-271.
277. Trecker C.C., Kozubal D.E., Quigg M., et al. Quality care in transverse myelitis: a responsive protocol. J Child Neurol 2009, 24:577-583.
278. Yavin Y., Cohan A.T. Venous thromboembolism prophylaxis for the medical patient: where do we stand?. Semin Respir Crit Care Med 2008, 29(1):75-82.
279. Anders J., Heinemann A., Carsten L., et al. Decubitus ulcers: pathophysiology and primary prevention. Dtsch Arztebl Int 2010, 107(21):371-382.
280. Putzke J., Richards J., Hicken B., et al. Predictors of life satisfaction: a spinal cord injury cohort study. Arch Phys Med Rehabil 2002, 83:555-561.
281. Ditunno P.L., Patrick M., Stineman M., et al. Who wants to walk? Preferences for recovery after SCI: a longitudinal and cross-sectional study. Spinal Cord 2008, 46:500-506.
282. Dietz V. Neurophysiology of gait disorders: present and future applications. Electroencephalogr Clin Neurophysiol 1997, 103(3):333-355.
283. Scivoletto G., Romanelli A., Mariotti A., et al. Clinical factors that affect walking level and performance in chronic spinal cord lesion patients. Spine (Phila Pa 1976) 2008, 33(3):259-264.
284. Lapointe R., Lajoie Y., Serresse O., et al. Functional community ambulation requirements in incomplete spinal cord injured subjects. Spinal Cord 2001, 39:327-335.
285. Sturt R.N., Holland A.E., New P.W. Walking ability at discharge from inpatient rehabilitation in a cohort of non-traumatic spinal cord injury patients. Spinal Cord 2009, 47(10):763-768.
286. Courtney A.M., Castro-Borrero W., Davis S.L., et al. Functional treatments in multiple sclerosis. Curr Opin Neurol 2011, 24(3):250-254.
287. Golzari Z., Shabkhiz F., Soudi S., et al. Combined exercise training reduces IFN-g and IL-17 levels in the plasma and the supernatant of peripheral blood mononuclear cells in women with multiple sclerosis. Int Immunopharmacol 2010, 10:1415-1419.
288. Hawker K., Frohman E., Racke M. Levetiracetam for phasic spasticity in multiple sclerosis. Arch Neurol 2003, 60:1772-1774.
289. Rittweger J., Gerrits K., Altenburg T., et al. Bone adaptation to altered loading after spinal cord injury: a study of bone and muscle strength. J Musculoskelet Neuronal Interact 2006, 6:269-276.
290. Roze E., Bounolleau P., Ducreux D., et al. Propriospinal myoclonus revisited: clinical, neurophysiologic, and neuroradiologic findings. Neurology 2009, 72(15):1301-1309.
291. Brown L.K., Heffner J.E., Obbens E.A. Tranverse myelitis associated with restless legs syndrome and periodic movements of sleep responsive to an oral dopaminergic agent but not to intrathecal baclofen. Sleep 2000, 23(5):1-4.
292. Natarajan R. Review of periodic limb movement and restless leg syndrome. J Postgrad Med 2010, 56(2):157-162.
293. Kalita J., Shah S., Kapoor R., et al. Bladder dysfunction in acute transverse myelitis: magnetic resonance imaging and neurophysiological and urodynamic correlations. J Neurol Neurosurg Psychiatry 2002, 73(2):154-159.
294. Gupta A., Taly A.B., Srivastava A., et al. Non-traumatic spinal cord lesions: epidemiology, complications, neurological and functional outcome of rehabilitation. Spinal Cord 2009, 47:307-311.
295. Tanaka S.T., Stone A.T., Kurzrock E.A. Transverse myelitis in children: long-term urological outcomes. J Urol 2006, 175(5):1864-1868.
296. Lemack G.E., Frohman E.M., Zimmern P.E., et al. Urodynamic distinctions between idiopathic detrusor overactivity and detrusor overactivity secondary to multiple sclerosis. Urology 2006, 67:960-964.
297. Samkoff L.M., Goodman A.D. Symptomatic management in multiple sclerosis. Neurol Clin 2011, 29(2):449-463.
298. Fowler C.J., Panicker J.N., Drake M., et al. A UK consensus on the management of the bladder in multiple sclerosis. Postgrad Med J 2009, 85(1008):552-559.
299. Ebert E. Gastrointestinal involvement in spinal cord injury: a clinical perspective. J Gastrointestin Liver Dis 2012, 21(1):75-82.
300. Raghav S., Kipp D., Watson J., et al. Gastroparesis in multiple sclerosis. Mult Scler 2006, 12(2):243-244.
301. Reddymasu S.C., Bonino J., McCallum R.W. Gastroparesis secondary to a demyelinating disease: a case series. BMC Gastroenterol 2007, 7:3.
302. Atkinson K., Romano W., Prokopiw I. An unusual cause of gastroparesis: demyelinating disease of the medulla. Dig Dis Sci 1998, 43:1430-1433.
303. Read S.J., Leggett B.A., Pender M.P. Gastroparesis with multiple sclerosis. Lancet 1995, 346(8984):1228.
304. Wiesel P.H., Norton C., Glickman S., et al. Pathophysiology and management of bowel dysfunction in multiple sclerosis. Eur J Gastroenterol Hepatol 2001, 13(4):441-448.
305. Christensen P., Krogh K., Buntzen S., et al. Long-term outcome and safety of transanal irrigation for constipation and fecal incontinence. Dis Colon Rectum 2009, 52:286-292.
306. Sexuality and reproductive health in adults with spinal cord injury: a clinical practice guideline for health-care professionals. J Spinal Cord Med 2010, 33(3):281-336. Consortium for Spinal Cord Medicine.
307. Lombardi G., Mondaini N., Iazzetta P., et al. Sexuality in patients with spinal cord injuries due to attempted suicide. Spinal Cord 2008, 46(1):53-57.
308. Forsythe E., Horsewell J.E. Sexual rehabilitation of women with a spinal cord injury. Spinal Cord 2006, 44:234-241.
309. Courtois F.J., Charvier K.F., Leriche A., et al. Sexual function in spinal cord injury men. Assessing sexual capability. Paraplegia 1993, 31:771-784.
310. Courtois F.J., Goulet M.C., Charvier K.F., et al. Posttraumatic erectile potential of spinal cord injured men: How physiologic recordings supplement subjective reports. Arch Phys Med Rehabil 1999, 80:1268-1272.
311. Alexander M.S., Biering-Sorensen F., Bodner D., et al. International standards to document remaining autonomic function after spinal cord injury. Spinal Cord 2009, 47:36-43.
312. Stone A.R. The sexual needs of the injured spinal cord patient. Probl Urol 1987, 1:529-536.
313. Barbonetti A., Cavallo F., Felzani G., et al. Erectile dysfunction is the main determinant of psychological distress in men with spinal cord injury. J Sex Med 2012, 9(3):830-836.
314. Anderson K.D., Borisoff J.F., Johnson R.D., et al. Long-term effects of spinal cord injury on sexual function in men: implications for neuroplasticity. Spinal Cord 2007, 45:338-348.
315. Lombardi G., Del Popolo G., Macchiarella A., et al. Sexual rehabilitation in women with spinal cord injury: a critical review of the literature. Spinal Cord 2010, 48(12):842-849.
316. Lombardi G., Mondaini N., Macchiarella A., et al. Female sexual dysfunction and hormonal status in spinal cord injured (SCI) patients. J Androl 2007, 28(5):722-726.
317. Soler J.M., Previnaire J.G. Ejaculatory dysfunction in spinal cord injury is suggestive of dyssynergic ejaculation. Eur J Phys Rehabil Med 2011, 47:677-681.
318. Kreuter M., Taft C., Siösteen A., et al. Women's sexual functioning and sex life after spinal cord injury. Spinal Cord 2011, 49(1):154-160.
319. Krassioukov A.V., Karlsson A.K., Wecht A.K., et al. Assessment of autonomic dysfunction following spinal cord injury: rationale for additions to International Standards for Neurological Assessment. J Rehabil Res Dev 2007, 44(1):103-112.
320. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology 1996, 46(5):1470.
321. Sidorov E.V., Townson A.F., Dvorak M.F., et al. Orthostatic hypotension in the first month following acute spinal cord injury. Spinal Cord 2008, 46(1):65-69.
322. Andersen E.B., Nordenbo A.M. Sympathetic vasoconstrictor responses in multiple sclerosis with thermo-regulatory dysfunction. Clin Auton Res 1997, 7:13-16.
323. Davis S.L., Wilson T.E., White A.T., et al. Thermoregulation in multiple sclerosis. J Appl Physiol 2010, 109(5):1531-1537.
324. Krassioukov A.V., Furlan J.C., Fehlings M.G. Autonomic dysreflexia in acute spinal cord injury: an under-recognized clinical entity. J Neurotrauma 2003, 20(8):707-718.
325. Krassioukov A., Warburton D.E., Teasell R., et al. A systematic review of the management of autonomic dysreflexia after spinal cord injury. Arch Phys Med Rehabil 2009, 90(4):682-695.
326. Braddom R.L., Rocco J.F. Autonomic dysreflexia. Am J Phys Med Rehabil 1991, 70:234-241.
327. Ho C.P., Krassioukov A.V. Autonomic dysreflexia and myocardial ischemia. Spinal Cord 2010, 48(9):714-715.
328. Chaves C.J., Lee G. Reversible posterior leukoencephalopathy in a patient with autonomic dysreflexia: a case report. Spinal Cord 2008, 46(11):760-761.
329. Dolinak D., Balraj E. Autonomic dysreflexia and sudden death in people with traumatic spinal cord injury. Am J Forensic Med Pathol 2007, 28(2):95-98.
330. Beard J.P., Wade W.H., Barber D.B. Sacral insufficiency stress fracture as etiology of positional autonomic dysreflexia: case report. Paraplegia 1996, 34(3):173-175.
331. Claydon V.E., Elliott S.L., Sheel A.W., et al. Cardiovascular responses to vibrostimulation for sperm retrieval in men with spinal cord injury. J Spinal Cord Med 2006, 29(3):207-216.
332. Szasz G., Carpenter C. Clinical observations in vibratory stimulation of the penis of men with spinal cord injury. Arch Sex Behav 1989, 18(6):461-474.
333. Blackmer J. Rehabilitation medicine: 1. Autonomic dysreflexia. CMAJ 2003, 169(9):931-935.
334. Sjölund B.H. Pain and rehabilitation after spinal cord injury: the case of sensory spasticity?. Brain Res Brain Res Rev 2002, 40:250-256.
335. Pollmann W., Feneberg W. Current management of pain associated with multiple sclerosis. CNS Drugs 2008, 22(4):291-324.
336. Bond L.D., Keough G.C. Neurogenic pruritus: a case of pruritus induced by transverse myelitis. Br J Dermatol 2003, 149(1):204-205.
337. Biering-Sorensen F., Bohr H., Schaadt O. Bone mineral content of the lumbar spine and lower extremities years after spinal cord lesion. Paraplegia 1988, 26:293-301.
338. Roberts D., Lee W., Cuneo R.C., et al. Longitudinal study of bone turnover after acute spinal cord injury. J Clin Endocrinol Metab 1998, 83:415-422.
339. Maïmoun L., Fattal C., Micallef J.P., et al. Bone loss in spinal cord-injured patients: from physiopathology to therapy. Spinal Cord 2006, 44(4):203-210.
340. Dionyssiotis Y. Spinal cord injury-related bone impairment and fractures: an update on epidemiology and physiopathological mechanisms. J Musculoskelet Neuronal Interact 2011, 11(3):257-265.
341. Naftchi N.E., Viau A.T., Sell G.H., et al. Mineral metabolism in spinal cord injury. Arch Phys Med Rehabil 1980, 61:139-142.
342. Oleson C.V., Patel P.H., Wuermser L.A. Influence of season, ethnicity, and chronicity on vitamin D deficiency in traumatic spinal cord injury. J Spinal Cord Med 2010, 33(3):202-213.
343. Pepe J., Romagnoli E., Nofroni I., et al. Vitamin D status as the major factor determining the circulating levels of parathyroid hormone: a study in normal subjects. Osteoporos Int 2005, 16(7):805-812.
344. Hiremath G.S., Cettomai D., Baynes M., et al. Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis. Mult Scler 2009, 15(6):735-740.
345. Asherio A., Munger K.L., Simon K.C. Vitamin D and multiple sclerosis. Lancet Neurol 2010, 9(6):599-612.
346. Munger K.L., Levin L.I., Hollis B.W., et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296(23):2832-2838.
347. Birmingham D.J., Hebert L.A., Song H., et al. Evidence that abnormally large seasonally declines in vitamin D status may trigger SLE flare in non-African Americans. Lupus 2012, 21(8):855-864.
348. Braun-Moscovici Y., Toledano K., Markovits D., et al. Vitamin D level: is it related to disease activity in inflammatory joint disease?. Rheumatol Int 2011, 31(4):493-499.
349. Mealy M.A., Newsome S., Greenberg B.M., et al. Low vitamin D levels and recurrent inflammatory spinal cord disease. Arch Neurol 2012, 69(3):352-356.
350. Gannage-Yared M.H., Azoury M., Mansour I., et al. Effects of a short-term calcium and vitamin D treatment on serum cytokines, bone markers, insulin and lipid concentrations in healthy post-menopausal women. J Endocrinol Invest 2003, 26(8):748-753.
351. Dickie L.J., Church L.D., Coulthard L.R., et al. Vitamin D3 down-regulates intracellular Toll-like receptor 9 expression and Toll-like receptor 9-induced IL-6 production in human monocytes. Rheumatology (Oxford) 2010, 49(8):1466-1471.
352. Correale J., Ysrraelit M.C., Gaitán M.I. Immunomodulatory effects of vitamin D in multiple sclerosis. Brain 2009, 132(5):1146-1160.
353. Tang J., Zhou R., Luger D., et al. Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. J Immunol 2009, 182(8):4624-4632.
354. Prietl B., Pilz S., Wolf M., et al. Vitamin D supplementation and regulatory T cells in apparently healthy subjects: vitamin D treatment for autoimmune diseases?. Isr Med Assoc J 2010, 12(3):136-139.
355. Holick M.F. Vitamin D: the underappreciated D-lightful hormone that is important for skeletal and cellular health. Current Opin Endocrinol Diabetes 2002, 9(1):87-98.
356. Hahn T.J., Hendin B.A., Scharp C.R., et al. Effect of chronic anticonvulsant therapy on serum 25-hydroxycholecalciferol levels in adults. N Engl J Med 1972, 287(18):900-904.
357. Vieth R. Critique of the considerations for establishing the tolerable upper intake for vitamin D: critical need for revision upwards. J Nutr 2006, 136:1117-1122.
358. Goldberg P., Flemin M.C., Picard E.H. Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypotheses 1986, 21:193-200.
359. Heaney R.P., Davies K.M., Chen T.C., et al. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003, 77:204-210.
360. Trang H.M., Cole D.E., Rubin L.A., et al. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr 1998, 68(4):854-858.
361. Giovannucci E., Liu Y., Rimm E.B., et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006, 98(7):451-459.
362. Robsahm T.E., Tretli S., Dahlback A., et al. Vitamin D3 from sunlight may improve the prognosis of breast, colon, and prostate cancer (Norway). Cancer Causes Control 2004, 15(2):149-158.
363. Mowe M., Haug E., Bohmer T. Low serum calcidiol concentration in older adults with reduced muscular function. J Am Geriatr Soc 1999, 47(2):220-226.
364. Pfeifer M., Begerow B., Minne H.W., et al. Vitamin D status, trunk muscle strength, body sway, falls, and fractures among 237 postmenopausal women with osteoporosis. Exp Clin Endocrinol Diabetes 2001, 109(2):87-92.
365. Plotkinoff G.A., Quigley B.A. Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. Mayo Clin Proc 2003, 78(12):1463-1470.
366. Patten S.B., Beck C.A., Williams J.V., et al. Major depression in multiple sclerosis: a population-based perspective. Neurology 2003, 61:1524-1527.
367. Mohr D.C., Goodkin D.E., Likosky W., et al. Treatment of depression improves adherence to interferon B-1b therapy for multiple sclerosis. Arch Neurol 1997, 54:531-533.
368. Edgar M.A. Nervous system involvement in ankylosing spondylitis. BMJ 1974, 1:394.
369. Oh D.H., Jun J.B., Kim H.T., et al. Transverse myelitis in a patient with longstanding ankylosing spondylitis. Clin Exp Rheumatol 2001, 19:195-196.
370. Lan H.H., Chen D.Y., Chen C.C., et al. Combination of transverse myelitis and arachnoiditis in cauda equina syndrome of long-standing ankylosing spondylitis: MRI features and its role in clinical management. Clin Rheumatol 2007, 26:1963-1967.
371. Rath J.J.G., Ronday H.K., Wirtz P.W. Acute transverse myelitis in psoriatic arthritis. J Neurol 2010, 257:457-458.
372. Weiss T.D., Nelson J.S., Woolsey R.M., et al. Transverse myelitis in mixed connective tissue disease. Arthritis Rheum 1978, 21(8):982-986.
373. Pedersen C., Bonen H., Boesen F. Transverse myelitis in mixed connective tissue disease. Case report. Clin Rheumatol 1987, 6:290-292.
374. Flechtner K.M., Baum K. Mixed connective tissue disease: recurrent episodes of optic neuropathy and transverse myelopathy. Successful treatment with plasmapheresis. J Neurol Sci 1994, 126:146-148.
375. Mok C.C., Lau C.S. Transverse myelopathy complicating mixed connective tissue disease. Case report. Clin Neurol Neurosurg 1995, 97:259-260.
376. Weatherby S.J.M., Davies M.B., Hawkins C.P. Transverse myelopathy, a rare complication of mixed connective tissue disease: comparison with SLE related transverse myelopathy. J Neurol Neurosurg Psychiatry 2000, 68:532-541.
377. Bhinder S., Harbour K., Majithia V. Transverse myelitis, a rare neurological manifestation of mixed connective tissue disease-a case report and a review of literature. Clin Rheumatol 2007, 26:445-447.
378. Torabi A.M., Patel R.K., Wolfe G.I., et al. Transverse myelitis in systemic sclerosis. Arch Neurol 2004, 61:126-128.
379. Franciotta D., Zardini E., Caporali R., et al. Systemic sclerosis in aquaporin-4 antibody-positive longitudinally extensive transverse myelitis. J Neurol Sci 2011, 303:139-141.
380. Brown J.J., Murphy M.J. Transverse myelopathy in progressive systemic sclerosis. Ann Neurol 1985, 17:615-617.
381. Averbuch-Heller L., Steiner I., Abramski O. Neurologic manifestations of progressive systemic sclerosis. Arch Neurol 1992, 49:1292-1295.
382. Ray D.W., Bridger J., Hawnaur J., et al. Transverse myelitis as the presentation of Jo-1 antibody syndrome (myositis and fibrosing alveolitis) in long-standing ulcerative colitis. Br J Rheumatol 1993, 32:1105-1108.
383. Bolla G., Disdier P., Verrot D., et al. Acute transverse myelitis and primary urticarial vasculitis. Clin Rheumatol 1998, 17:250-252.
384. Nakashima I., Fujihara K., Endo M., et al. Clinical and laboratory features of myelitis patients with anti-neutrophil cytoplasmic antibodies. J Neurol Sci 1998, 157(1):60-66.
385. Hamilton A.J., Whitehead D.J., Bull M.D., et al. Systemic pANCA-associated vasculitis with central nervous involvement causing recurrent myelitis: case report. BMC Neurol 2010, 10:118.
386. Bürk K., Farecki M.L., Lamprecht G., et al. Neurological symptoms in patients with biopsy proven celiac disease. Mov Disord 2009, 24:2358-2362.
387. Hammond E.R., Pardo C.A., Kerr D.A. Thymic hyperplasia in a patient with recurrent transverse myelitis with clinical resolution after thymectomy. J Neurol Neurosurg Psychiatry 2008, 79:334-335.
388. Drobyski W.R., Potluri J., Sauer D., et al. Autoimmune hemolytic anemia following T-cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transplant 1996, 17:1093-1099.
389. Richard S., Fruchtman S., Scigliano E., et al. An immunological syndrome featuring transverse myelitis, Evans syndrome and pulmonary infiltrates after unrelated bone marrow transplant in a patient with severe aplastic anemia. Bone Marrow Transplant 2000, 26:1225-1228.
390. Perez-Montes R., Richard C., Baro J., et al. Acute transverse myelitis and autoimmune pancytopenia after unrelated hematopoietic cell transplantation. Haematologica 2001, 86(5):556-557.
391. Kumar N., Hagan J.B., Abraham R.S., et al. Common variable immunodeficiency-associated myelitis: report of treatment with infliximab. J Neurol 2008, 255(11):1821-1824.
392. Hermaszewski R.A., Webster A.D. Primary hypogammaglobulinemia: a survey of clinical manifestations and complications. Q J Med 1993, 86:31-42.
393. Leypoldt F., Eichhorn P., Saager C., et al. Successful immunosuppressive treatment and long-term follow-up of anti-Ri-associated paraneoplastic myelitis. J Neurol Neurosurg Psychiatry 2006, 77(10):1199-1200.
394. Pittock S.J., Lucchinetti C.F., Lennon V.A. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 2003, 53(5):580-587.
395. Pittock S.J., Lucchinetti C.F., Parisi J.E., et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol 2005, 58:96-107.
396. Chamard L., Magnin E., Berger E., et al. Stiff leg syndrome and myelitis with anti-amphiphysin antibodies: a common physiopathology?. Eur Neurol 2011, 66:253-255.
397. Saiz A., Blanco Y., Sabater L., et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 2008, 131:2553-2563.
398. Vitaliani R., Mason W., Ances B., et al. Paraneoplastic encephalitis, psychiatric symptoms and hypoventilation in ovarian teratoma. Ann Neurol 2005, 58:594-604.
399. Kruer M.C., Koch T.K., Bourdette D.N., et al. NMDA receptor encephalitis mimicking seronegative neuromyelitis optica. Neurology 2010, 74:1473-1475.
400. Pennington C., Livingstone S., Santosh C., et al. N-Methyl-D-aspartate receptor antibody encephalitis associated with myelitis. J Neurol Sci 2012, 317:151-153.
401. Cay H.F., Gungor H.A., Sezer I., et al. Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report. J Clin Pharm Ther 2006, 31(6):645-648.
402. Saieg N.A., Luzar M.J. Etanercept induced multiple sclerosis and transverse myelitis. J Rheumatol 2006, 33:1202-1204.
403. Oleginski T.P., Harrington T.M., Carlson J.P. Transverse myelitis secondary to sulfasalazine. J Rheumatol 1991, 18(2):304.
404. Zhang M., Li B., Li J. Acute transverse myelopathy probably related to intravenous gemcitabine plus cisplatin. Ann Pharmacother 2011, 45(4):544-545.
405. Wang M.Y., Arnold A.C., Vinters H.V., et al. Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy. Am J Ophthalmol 2000, 130:367-368.
406. Baker W.J., Royer G.L., Weiss R.B. Cytarabine and neurologic toxicity. J Clin Oncol 1991, 9:679-693.
407. Resar L., Phillips P., Kastan M., et al. Acute neurotoxicity after intrathecal cytosine arabinoside in two adolescents with acute lymphoblastic leukemia of B-cell type. Cancer 1993, 71:117-123.
408. Crawford S., Rustin G., Bagshawe K. Acute neurological toxicity of intrathecal cytosine arabinoside: a case report. Cancer Chemother Pharmacol 1986, 16:306-307.
409. Dinsdale T. Spinal analgesia and cauda equina lesions. Anaesthesia 1947, 2:17-27.
410. Dawkins C.J. An analysis of the complications of extradural and caudal block. Anaesthesia 1969, 24:554-563.
411. Newberry J.M. Paraplegia following general anaesthesia. Anaesthesia 1977, 32:78-79.
412. Schreiner E.J., Lipson S.F., Bromage P.R., et al. Neurological complications following general anaesthesia. Three cases of major paralysis. Anaesthesia 1983, 38:226-229.
413. Kitching A., Taylor S. A postoperative neurological problem. Anaesthesia 1989, 44:695-696.
414. Gutowsky N.J., Davies A.O. Transverse myelitis following general anaesthesia. Anaesthesia 1993, 48:44-45.
415. Martinez-Garcia E., Pelaez E., Roman J.C., et al. Transverse myelitis following general and epidural anaesthesia in a paediatric patient. Anaesthesia 2005, 60:921-923.
416. Richter R.W., Rosenberg R.N. Transverse myelitis associated with heroin addiction. JAMA 1968, 206(6):1255-1257.
417. Ell J.J., Uttley D., Silver J.R. Acute myelopathy in association with heroin addiction. J Neurol Neurosurg Psychiatry 1981, 44:448-450.
418. McCreary M., Emerman C., Hanna J., et al. Acute myelopathy following intranasal insufflation of heroin: a case report. Neurology 2000, 55:316-317.
419. Sahni V., Garg D., Garg S., et al. Unusual complications of heroin abuse: transverse myelitis, rhabdomyolysis, compartment syndrome, and ARF. Clin Toxicol (Phila) 2008, 46(2):153-155.
420. Herregods P., Chappel R., Mortier G. Benzene poisoning as a possible cause of transverse myelitis. Paraplegia 1984, 22:305-310.
421. Sauer G.C. Transverse myelitis and paralysis from a brown recluse spider bite. Mo Med 1975, 72(10):603-604.
422. Misra U.K., Kalita K. Comparison of clinical and electrodiagnostic features in B12 deficiency neurological syndromes with and without antiparietal cell antibodies. Postgrad Med J 2007, 83(976):124-127.
423. Lindenbaum J., Healton E.B., Savage D.G., et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med 1988, 318(26):1720-1728.
424. Naidich M.J., Ho S.U. Case 87: subacute combined degeneration. Radiology 2005, 237:101-105.
425. Paliwal V.K., Malhotra H.S., Chaurasia R.N., et al. "Anchor" -shaped bright posterior column in a patient with vitamin B12 deficiency myelopathy. Postgrad Med J 2009, 85:186.
426. Vorgerd M., Tegenthoff M., Kuhne D., et al. Spinal MRI in progressive myeloneuropathy associated with vitamin E deficiency. Neuroradiology 1996, 38:S111-S113.
427. Gutmann L., Shockor W., Gutmann L., et al. Vitamin E-deficient spinocerebellar syndrome due to intestinal lymphangiectasia. Neurology 1986, 36(4):554-556.
428. Nelson J.S., Fitch C.D., Fischer V.W., et al. Progressive neuropathologic lesions in vitamin E deficient rhesus monkeys. J Neuropathol Exp Neurol 1981, 40:166-186.
429. Pineles S.L., Wilson C.A., Balcer L.J., et al. Combined optic neuropathy and myelopathy secondary to copper deficiency. Surv Ophthalmol 2010, 55(4):386-392.
430. Naismith R.T., Shepherd J.B., Weihl C.C., et al. Acute and bilateral blindness due to optic neuropathy associated with copper deficiency. Arch Neurol 2009, 66(8):1025-1027.
431. Nations S.P., Boyer P.J., love L.A., et al. Denture cream: an unusual source of excess zinc leading to hypocupremia and neurologic disease. Neurology 2008, 71(9):639-643.
432. Kumar N. Copper deficiency myelopathy (human swayback). Mayo Clin Proc 2006, 81(10):1371-1384.
433. Jaiser S.R., Winston G.P. Copper deficiency myelopathy. J Neurol 2010, 257:869-881.
434. Tatum W.O., Bui D.D., Grant E.G., et al. Pseudo-Guillain-Barre syndrome due to "whippet"-induced myeloneuropathy. J Neuroimaging 2010, 20(4):400-401.
435. Renard D., Dutray A., Remy A., et al. Subacute combined degeneration of the spinal cord caused by nitrous oxide anaesthesia. Neurol Sci 2009, 30(1):75-76.
436. Ng J., O'Grady G., Pettit T., et al. Nitrous oxide use in first-year students at Auckland University. Lancet 2009, 361:1349-1350.
437. Spencer P.S., Ludoph A.C., Kisby G.E. Neurologic diseases associated with use of plant components with toxic potential. Environ Res 1993, 62:106-113.
438. Gerstner E.R., Batchelor T.T. Primary central nervous system lymphoma. Arch Neurol 2010, 67(3):291-297.
439. Herrlinger U., Weller M., Kuker W. Primary CNS lymphoma in the spinal cord: clinical manifestations may precede MRI detectability. Neuroradiology 2002, 44(3):239-244.
440. Flanagan E.P., O'Neill B.P., Porter A.B., et al. Primary intramedullary spinal cord lymphoma. Neurology 2011, 77(8):784-791.
441. Beristain X., Azzarelli B. The neurological masquerade of intravascular lymphomatosis. Arch Neurol 2002, 59:439-443.
442. Grove C.S., Robbins P.D., Kermode A.G. Intravascular lymphoma presenting as progressive paraparesis. J Clin Neurosci 2008, 15:1056-1058.
443. Yang T., Tian L., Li Q., et al. A case of intravascular B-cell lymphoma presenting as myelopathy and diagnosed postmortem. J Neurol Sci 2008, 272:196-198.
444. Kumar N., Keegan A.M., Rodriguez F.J., et al. Intravascular lymphoma presenting as a longitudinally-extensive myelitis: diagnostic challenges and etiologic clues. J Neurol Sci 2011, 303:146-149.
445. Podnar S. Epidemiology of cauda equina and conus medullaris lesions. Muscle Nerve 2007, 35:529-531.
446. Schwarz S., Zoubaa S., Knauth M., et al. Intravascular lymphomatosis presenting with a conus medullaris syndrome mimicking disseminated encephalomyelitis. Neuro Oncol 2002, 4(3):187-191.
447. Zeng M., Knisely J. Post-radiotherapy myelitis observed in an AIDS patient with a meningioma: case report and review of the literature. J Neurooncol 1999, 45(2):167-174.
448. Rampling R., Symonds P. Radiation myelopathy. Curr Opin Neurol 1998, 11(6):627-632.
449. Bleyer A., Choi M., Wang S.J., et al. Increased vulnerability of the spinal cord to radiation or intrathecal chemotherapy during adolescence: a report from the Children's Oncology Group. Pediatr Blood Cancer 2009, 53:1205-1210.
450. Alfonso E.R., De Gregorio M.A., Mateo P., et al. Radiation myelopathy in over-irradiated patients: MR imaging findings. Eur Radiol 1997, 7(3):400-404.
451. Behrman A.L., Harkema S.J. Physical rehabilitation as an agent for recovery after spinal cord injury. Phys Med Rehabil Clin N Am 2007, 18(2):183-202.
452. Atrice M.B. Lower extremity orthotic management for the spinal-cord-injured client. Spinal Cord Inj Rehabil 2000, 5(4):1-10.
453. Bailey S.N., Hardin E.C., Kobetic R., et al. Neurotherapeutic and neuroprosthetic effects of implanted functional electrical stimulation for ambulation after incomplete spinal cord injury. J Rehabil Res Dev 2010, 47(1):7-16.
454. Everaert D.G., Thompson A.K., Chong S.L., et al. Does functional electrical stimulation for foot drop strengthen corticospinal connections?. Neurorehabil Neural Repair 2010, 24:168-177.
455. Swinnen E., Duerinck S., Baeyens J.P., et al. Effectiveness of robot-assisted gait training in persons with spinal cord injury: a systematic review. J Rehabil Med 2010, 42:520-526.
456. Jung R., Belanger A., Kanchiku T., et al. Neuromuscular stimulation therapy after incomplete spinal cord injury promotes recovery of interlimb coordination during locomotion. J Neural Eng 2009, 6(5):055010. 10.1088/1741-2560/6/5/055010.
457. Goodman A.D., Brown T.R., Edwards K.R., et al. A phase 3 trial of extended release oral dalframpridine in multiple sclerosis. Ann Neurol 2010, 68(4):494-502.
458. Kalsi V., Gonzales G., Popat R., et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 2007, 62(5):452-457.
459. Morton S.C., Shekelle P.G., Adams J.L., et al. Antimicrobial prophylaxis for urinary tract infection in persons with spinal cord dysfunction. Arch Phys Med Rehabil 2002, 83:129-138.
460. Hess M.J., Hess P.E., Sullivan M.R., et al. Evaluation of cranberry tablets for the prevention of urinary tract infections in spinal cord injured patients with neurogenic bladder. Spinal Cord 2008, 46:622-626.
461. Bosma R., Wynia K., Havlikova E., et al. Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis. Acta Neurol Scand 2005, 112(1):1-5.
462. Khan F., Pallant J.F., Pallant J.I., et al. A randomised controlled trial: outcomes of bladder rehabilitation in persons with multiple sclerosis. J Neurol Neurosurg Psychiatry 2010, 81:1033-1038.
463. Dasgupta P., Haslam C., Goodwin R., et al. The 'Queen Square bladder stimulator': a device for assisting emptying of the neurogenic bladder. Br J Urol 1997, 80(2):234-237.
464. Prasad R.S., Smith S.J., Wright H. Lower abdominal pressure versus external bladder stimulation to aid bladder emptying in multiple sclerosis: a randomized controlled study. Clin Rehabil 2003, 17(1):42-47.
465. Schwendimann R.N. Treatment of symptoms in multiple sclerosis. Neurol Res 2006, 28:306-315.
466. Bywater A., While A. Management of bowel dysfunction in people with multiple sclerosis. Br J Community Nurs 2006, 11(8):333-341.
467. Wiesel P.H., Norton C., Roy A.J., et al. Gut focused behavioural treatment (biofeedback) for constipation and faecal incontinence in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000, 69(2):240-243.
468. Lombardi G., Macchiarella A., Cecconi F., et al. Ten-year follow-up of sildenafil use in spinal cord-injured patients with erectile dysfunction. J Sex Med 2009, 6(12):3449-3457.
469. Lombardi G., Nelli F., Celso M., et al. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature. J Sex Med 2012, 9(4):970-985.
470. Dimitriadis T., Karakitsios K., Tsounapi P., et al. Erectile function and male reproduction in men with spinal cord injury: a review. Andrologia 2010, 42(3):139-165.
471. Sipski M.L., Alexander C.J., Gomez-Marin O., et al. Effects of vibratory stimulation on sexual response in women with spinal cord injury. J Rehabil Res Dev 2005, 42(5):609-616.
472. Billups K.L., Berman L., Berman J., et al. A new non-pharmacological vacuum therapy for female sexual dysfunction. J Sex Marital Ther 2001, 27:435-441.
473. Lahrmann H., Cortelli P., Hilz M., et al. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol 2006, 13(9):930-936.
474. Faghri P.D., Yount J. Electrically induced and voluntary activation of physiologic muscle pump: a comparison between spinal cord-injured and able-bodied individuals. Clin Rehabil 2002, 16(8):878-885.
475. Raymond J., Davis G.M., Bryant G., et al. Cardiovascular responses to an orthostatic challenge and electrical-stimulation-induced leg muscle contractions in individuals with paraplegia. Eur J Appl Physiol Occup Physiol 1999, 80(3):205-212.
476. Low P.A., Gilden J.L., Freeman R., et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine study group. JAMA 1997, 277(13):1046-1051.
477. Singer W., Sandroni P., Opfer-Gehrking T.L., et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol 2006, 63(4):513-518.
478. Mathias C.J., Senard J.M., Braune S., et al. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res 2001, 11:235-242.
479. Rabchevsky A.G., Patel S.P., Duale H., et al. Gabapentin for spasticity and autonomic dysreflexia after severe spinal cord injury. Spinal Cord 2011, 49(1):99-105.
480. Frankel H.L., Mathias C.J. Severe hypertension in patients with high spinal cord lesions undergoing electro-ejaculation-management with prostaglandin E2. Paraplegia 1980, 18(5):293-299.